image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 4.27
-1.16 %
$ 137 M
Market Cap
-1.02
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NOTV stock under the worst case scenario is HIDDEN Compared to the current market price of 4.27 USD, Inotiv, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NOTV stock under the base case scenario is HIDDEN Compared to the current market price of 4.27 USD, Inotiv, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one NOTV stock under the best case scenario is HIDDEN Compared to the current market price of 4.27 USD, Inotiv, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
491 M REVENUE
-14.27%
-86.4 M OPERATING INCOME
-6.07%
-109 M NET INCOME
-3.80%
-6.8 M OPERATING CASH FLOW
-24.41%
-16.8 M INVESTING CASH FLOW
41.46%
9.68 M FINANCING CASH FLOW
-39.04%
130 M REVENUE
23.28%
-13.2 M OPERATING INCOME
36.55%
-18.9 M NET INCOME
27.58%
-2.37 M OPERATING CASH FLOW
83.98%
-5.25 M INVESTING CASH FLOW
-77.75%
14.6 M FINANCING CASH FLOW
1931.95%
Balance Sheet Inotiv, Inc.
image
Current Assets 163 M
Cash & Short-Term Investments 21.4 M
Receivables 73.6 M
Other Current Assets 68.4 M
Non-Current Assets 618 M
Long-Term Investments 0
PP&E 237 M
Other Non-Current Assets 380 M
Current Liabilities 119 M
Accounts Payable 33.5 M
Short-Term Debt 15.3 M
Other Current Liabilities 70.2 M
Non-Current Liabilities 492 M
Long-Term Debt 0
Other Non-Current Liabilities 492 M
EFFICIENCY
Earnings Waterfall Inotiv, Inc.
image
Revenue 491 M
Cost Of Revenue 380 M
Gross Profit 111 M
Operating Expenses 198 M
Operating Income -86.4 M
Other Expenses 22.5 M
Net Income -109 M
RATIOS
22.65% GROSS MARGIN
22.65%
-17.61% OPERATING MARGIN
-17.61%
-22.10% NET MARGIN
-22.10%
-63.60% ROE
-63.60%
-13.88% ROA
-13.88%
-38.72% ROIC
-38.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inotiv, Inc.
image
Net Income -109 M
Depreciation & Amortization 57.1 M
Capital Expenditures -22.3 M
Stock-Based Compensation 6.74 M
Change in Working Capital 52.6 M
Others 8.48 M
Free Cash Flow -29.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inotiv, Inc.
image
Wall Street analysts predict an average 1-year price target for NOTV of $6.33 , with forecasts ranging from a low of $4 to a high of $10 .
NOTV Lowest Price Target Wall Street Target
4 USD -6.32%
NOTV Average Price Target Wall Street Target
6.33 USD 48.32%
NOTV Highest Price Target Wall Street Target
10 USD 134.19%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Inotiv, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
728 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 19, 2024
Bought 100 K USD
Landman David
Director
+ 23529
4.25 USD
1 month ago
Dec 10, 2024
Bought 142 K USD
Beattie John Gregory
Chief Operating Officer
+ 30000
4.75 USD
1 month ago
Dec 10, 2024
Bought 32 K USD
Brown Nigel
Director
+ 7500
4.26 USD
1 month ago
Dec 06, 2024
Bought 39.8 K USD
Harrington Michael J
Director
+ 10000
3.9822 USD
1 month ago
Dec 06, 2024
Bought 414 K USD
Landman David
Director
+ 100000
4.14 USD
5 years ago
Jun 07, 2019
Bought 14.9 K USD
Leasure Robert Jr.
President and CEO
+ 7500
1.9819 USD
1 year ago
Dec 14, 2023
Bought 14.1 K USD
Garrett Michael
Chief Commercial Officer
+ 5000
2.829 USD
1 year ago
Dec 14, 2023
Bought 150 K USD
Beattie John Gregory
Chief Operating Officer
+ 47966
3.1238 USD
1 year ago
Mar 14, 2023
Bought 25 K USD
Sagartz John E
Chief Strategy Officer
+ 5100
4.91 USD
1 year ago
Feb 22, 2023
Bought 35 K USD
Beattie John Gregory
Chief Operating Officer
+ 5000
6.99 USD
2 years ago
Dec 09, 2022
Sell 12.4 K USD
Pitchford William D
Chief Human Resources Officer
- 2123
5.8246 USD
2 years ago
Dec 01, 2022
Sell 6.12 K USD
Neff R Matthew
Director
- 1000
6.12 USD
2 years ago
Nov 01, 2022
Sell 10.6 K USD
Neff R Matthew
Director
- 500
21.1201 USD
2 years ago
Nov 01, 2022
Sell 10.6 K USD
Neff R Matthew
Director
- 500
21.1261 USD
2 years ago
Oct 17, 2022
Sell 19.1 K USD
Neff R Matthew
Director
- 1000
19.1 USD
2 years ago
Mar 15, 2022
Bought 76.3 K USD
Harkness James
Chief Operating Officer, RMS
+ 4049
18.84 USD
2 years ago
Feb 18, 2022
Bought 26.4 K USD
Davis Gregory Cole
Director
+ 1250
21.12 USD
2 years ago
Feb 18, 2022
Bought 59.8 K USD
Davis Gregory Cole
Director
+ 2500
23.9255 USD
2 years ago
Feb 17, 2022
Bought 25.7 K USD
Davis Gregory Cole
Director
+ 1250
20.571 USD
2 years ago
Feb 17, 2022
Bought 115 K USD
Leasure Robert Jr.
President and CEO
+ 5000
23.0262 USD
2 years ago
Feb 17, 2022
Bought 50 K USD
Sagartz John E
Chief Strategy Officer
+ 2506
19.9516 USD
3 years ago
Dec 22, 2021
Sell 132 K USD
Downing Philip A
Sr. VP, Preclinical Srvcs.
- 3057
43.0412 USD
3 years ago
Jun 07, 2021
Bought 50 K USD
Sagartz John E
Chief Strategy Officer
+ 1742
28.7 USD
3 years ago
May 28, 2021
Bought 49.9 K USD
Sagartz John E
Chief Strategy Officer
+ 2012
24.78 USD
3 years ago
May 27, 2021
Bought 120 USD
Sagartz John E
Chief Strategy Officer
+ 5
24 USD
7. News
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock on December 30, 2024. globenewswire.com - 2 weeks ago
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024. globenewswire.com - 3 weeks ago
Inotiv, Inc. Launches Proposed Public Offering of Common Shares WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com - 1 month ago
Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript Inotiv, Inc. (NASDAQ:NOTV ) Q4 2024 Earnings Conference Call December 3, 2024 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to today's Inotiv Fiscal 2024 Fourth Quarter Financial Results. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update —  Enhanced liquidity through issuance of Second Lien Notes —  Obtained amendment to credit agreement and extended note payable —  Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million —  Full year fiscal 2024 revenue down 14.3% to $490.7 million —  Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2024”) and twelve months ("FY 2024") ended September 30, 2024. globenewswire.com - 1 month ago
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth globenewswire.com - 1 month ago
Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. globenewswire.com - 1 month ago
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering. globenewswire.com - 4 months ago
Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City. globenewswire.com - 4 months ago
Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript Inotiv, Inc. (NASDAQ:NOTV ) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Eric Coldwell - Baird Operator Good day, everyone and welcome to this Inotiv Third Quarter Earnings Conference Call. [Operator Instructions] And it's now my pleasure to turn the floor over to Mr. seekingalpha.com - 5 months ago
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.07 per share a year ago. zacks.com - 5 months ago
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. globenewswire.com - 5 months ago
8. Profile Summary

Inotiv, Inc. NOTV

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 137 M
Dividend Yield 0.00%
Description Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Contact 2701 Kent Avenue, West Lafayette, IN, 47906-1382 https://www.inotivco.com
IPO Date Nov. 25, 1997
Employees 1955
Officers Ms. Beth A. Taylor CPA Senior Vice President of Finance & Chief Financial Officer Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D. Chief Strategy Officer & Director Mr. John Gregory Beattie DSA Chief Operating Officer of DSA Mr. Robert W. Leasure Jr. President, Chief Executive Officer & Director Dr. Peter T. Kissinger Founder, Chairman Emeritus & Scientific Advisor Mr. Brennan Freeman Vice President of Finance, Principal Accounting Officer & Corporate Controller Ms. Andrea Castetter SVice President of General Counsel, Corporate Secretary & Chief Compliance Officer Mr. Jeffrey Arthur Krupp Chief Human Resources Officer Dr. Adrian Hardy Ph.D. Chief Commercial Officer Ms. Lizanne Muller Group President of RMS